-
1
-
-
34248586934
-
Medicaid's Prior Authorization Program and Access to Atypical Antipsychotic Medications
-
J.M. Polinski, P.S. Wang, and M.A. Fischer, "Medicaid's Prior Authorization Program and Access to Atypical Antipsychotic Medications," Health Affairs 26. no. 3 (2007): 750-760;
-
(2007)
Health Affairs
, vol.26
, Issue.3
, pp. 750-760
-
-
Polinski, J.M.1
Wang, P.S.2
Fischer, M.A.3
-
2
-
-
17244370794
-
Medicaid Policies to Contain Psychiatric Drug Costs
-
and C. Koyanagi, S. Forquer, and E. Alfano, "Medicaid Policies to Contain Psychiatric Drug Costs," Health Affairs 24, no. 2 (2005): 536-544.
-
(2005)
Health Affairs
, vol.24
, Issue.2
, pp. 536-544
-
-
Koyanagi, C.1
Forquer, S.2
Alfano, E.3
-
3
-
-
33947611154
-
-
Polinski et al, Medicaid's Prior Authorization Program; and H.A. Huskamp et al., Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D, Psychiatric Services 58, no. 3 (2007): 308-310.
-
Polinski et al, "Medicaid's Prior Authorization Program"; and H.A. Huskamp et al., "Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D," Psychiatric Services 58, no. 3 (2007): 308-310.
-
-
-
-
5
-
-
2942648152
-
Schizophrenia
-
K.T. Mueser and S.R. McGurk, "Schizophrenia," Lancet 363, no. 9426 (2004): 2063-2072,
-
(2004)
Lancet
, vol.363
, Issue.9426
, pp. 2063-2072
-
-
Mueser, K.T.1
McGurk, S.R.2
-
6
-
-
0142244688
-
-
and R. Freedman, Schizophrenia, New England Journal of Medicine 349, no. 18 (2003): 1738-1749.
-
and R. Freedman, "Schizophrenia," New England Journal of Medicine 349, no. 18 (2003): 1738-1749.
-
-
-
-
7
-
-
0035154103
-
Clinical Outcome Following Neuroleptic Discontinuation in Patients with Remitted Recent-Onset Schizophrenia
-
M. Gitlin et al., "Clinical Outcome Following Neuroleptic Discontinuation in Patients with Remitted Recent-Onset Schizophrenia," American Journal of Psychiatry 158, no. 11 (2001): 1835-1842.
-
(2001)
American Journal of Psychiatry
, vol.158
, Issue.11
, pp. 1835-1842
-
-
Gitlin, M.1
-
8
-
-
44449090754
-
-
Mueser and McGurk, Schizophrenia;
-
Mueser and McGurk, "Schizophrenia";
-
-
-
-
9
-
-
25144456112
-
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
-
J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no. 12 (2005): 1209-1223;
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.12
, pp. 1209-1223
-
-
Lieberman, J.A.1
-
11
-
-
39549111228
-
A Longitudinal Study of Medication Non-Adherence and Hospitalization Risk in Schizophrenia
-
and M.R. Law et al., "A Longitudinal Study of Medication Non-Adherence and Hospitalization Risk in Schizophrenia," Journal of Clinical Psychiatry 69, no. 1 (2008): 47-53.
-
(2008)
Journal of Clinical Psychiatry
, vol.69
, Issue.1
, pp. 47-53
-
-
Law, M.R.1
-
12
-
-
44449177331
-
-
Mueser and McGurk, Schizophrenia;
-
Mueser and McGurk,, "Schizophrenia";
-
-
-
-
13
-
-
44449156935
-
Effectiveness of Antipsychotic
-
Lieberman et al., "Effectiveness of Antipsychotic Drugs";
-
Drugs
-
-
Lieberman1
-
14
-
-
0036886986
-
Safety and Tolerability: How Do Newer Generation 'Atypical' Antipsychotics Compare?
-
and R. Tandon, "Safety and Tolerability: How Do Newer Generation 'Atypical' Antipsychotics Compare?" Psychiatric Quarterly 73, no. 4 (2002): 297-311.
-
(2002)
Psychiatric Quarterly
, vol.73
, Issue.4
, pp. 297-311
-
-
Tandon, R.1
-
15
-
-
4344699183
-
Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid
-
S.B. Soumerai, "Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid," Health Affairs 23, no. 1 (2004): 135-146.
-
(2004)
Health Affairs
, vol.23
, Issue.1
, pp. 135-146
-
-
Soumerai, S.B.1
-
16
-
-
44449179553
-
-
National Alliance on Mental Illness Maine, accessed 1 February 2008
-
National Alliance on Mental Illness Maine, "Calls in Response to the 2003 Implementation of Limits on Access to MaineCare Medications," http://www.nami.org/Content/Microsites186/NAMI_Maine/Home174/Whats_New89/ NAMI_Maine_Monitered_Issues/RXaccess.pdf (accessed 1 February 2008).
-
Calls in Response to the 2003 Implementation of Limits on Access to MaineCare Medications
-
-
-
17
-
-
0028169466
-
Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia
-
S.B. Soumerai et al., "Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia," New England Journal of Medicine 331, no. 10 (1994): 650-655.
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.10
, pp. 650-655
-
-
Soumerai, S.B.1
-
19
-
-
0026719581
-
Does Capitation Affect the Health of the Chronically Mentally Ill? Results from a Randomized Trial
-
and N. Lurie et al., "Does Capitation Affect the Health of the Chronically Mentally Ill? Results from a Randomized Trial," Journal of the American Medical Association 267, no. 24 (1992): 3300-3304.
-
(1992)
Journal of the American Medical Association
, vol.267
, Issue.24
, pp. 3300-3304
-
-
Lurie, N.1
-
21
-
-
44449156935
-
Effectiveness of Antipsychotic
-
Lieberman et al., "Effectiveness of Antipsychotic Drugs."
-
Drugs
-
-
Lieberman1
-
22
-
-
0035500992
-
Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies Using Claims Data
-
S. Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies Using Claims Data," American Journal of Epidemiology 154, no. 9 (2001): 854-864.
-
(2001)
American Journal of Epidemiology
, vol.154
, Issue.9
, pp. 854-864
-
-
Schneeweiss, S.1
-
24
-
-
77957888445
-
Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals
-
D. Lin, L. Wei, and Z. Ying, "Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals," Biometrika 80, no. 3 (1993): 557-572.
-
(1993)
Biometrika
, vol.80
, Issue.3
, pp. 557-572
-
-
Lin, D.1
Wei, L.2
Ying, Z.3
-
26
-
-
0036359656
-
Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research
-
and A.K. Wagner et al., "Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research," Journal of Clinical Pharmacy and Therapeutics 27, no. 4 (2002): 299-309.
-
(2002)
Journal of Clinical Pharmacy and Therapeutics
, vol.27
, Issue.4
, pp. 299-309
-
-
Wagner, A.K.1
-
28
-
-
44449173260
-
-
For more details regarding the effects of the policy on medication use, see the online appendix at
-
For more details regarding the effects of the policy on medication use, see the online appendix at http://content.healthaffairs.org/cgi/content/full/ hlthaff.27.3.185/DC2.
-
-
-
-
29
-
-
44449115406
-
-
See Exhibit A2 in the online appendix; ibid.
-
See Exhibit A2 in the online appendix; ibid.
-
-
-
-
30
-
-
3543124260
-
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients with Schizophrenia
-
P.J. Weiden et al., "Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients with Schizophrenia," Psychiatric Services 55, no. 8 (2004): 886-891;
-
(2004)
Psychiatric Services
, vol.55
, Issue.8
, pp. 886-891
-
-
Weiden, P.J.1
-
33
-
-
4444242571
-
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
-
D.L. Leslie and R.A. Rosenheck, "Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications," American Journal of Psychiatry 161, no. 9 (2004): 1709-1711.
-
(2004)
American Journal of Psychiatry
, vol.161
, Issue.9
, pp. 1709-1711
-
-
Leslie, D.L.1
Rosenheck, R.A.2
-
35
-
-
0037734369
-
Effect of a Mental Health 'Carve-Out' Program on the Continuity of Antipsychotic Therapy
-
and W.A. Ray, J.R. Daugherty, and K.G. Meador, "Effect of a Mental Health 'Carve-Out' Program on the Continuity of Antipsychotic Therapy," New England Journal of Medicine 348, no. 19 (2003): 1885-1894.
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.19
, pp. 1885-1894
-
-
Ray, W.A.1
Daugherty, J.R.2
Meador, K.G.3
-
39
-
-
44449139221
-
-
State of Maine, Department of Health and Human Services, Office of Maine Care Services, Version, accessed 6 March
-
State of Maine, Department of Health and Human Services, Office of Maine Care Services, "MaineCare PDL with Criteria (07.01.07), PDF Version," http://www.mainecarepdl.org/index.pl/pdlfiles/mainecarepdl/copy-of-ssdc- pdl_maine-6_25_07-without-criteria2.pdf (accessed 6 March 2008);
-
(2008)
MaineCare PDL with Criteria (07.01.07), PDF
-
-
-
40
-
-
44449132909
-
-
Version, accessed 6 March
-
and "MaineCare PDL (MEDEL Combined) with Criteria (01.31.08), PDF Version," http://www.mainecarepdl.org/index.pl/index7.pl/pdlfiles/ mainecare-pdl/ssdc-pdl_maine-1_1_08-with-criteria.pdf (accessed 6 March 2008).
-
(2008)
MaineCare PDL (MEDEL Combined) with Criteria (01.31.08), PDF
-
-
-
41
-
-
44449137216
-
-
Spring, accessed 24 March 2008
-
MaineCare, "Pharmacy Benefit Update," Spring 2007, http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings (accessed 24 March 2008).
-
(2007)
Pharmacy Benefit Update
-
-
MaineCare1
-
42
-
-
44449160141
-
Medicare Modernization Act
-
accessed 1 February 2008
-
Centers for Medicare and Medicaid Services, "Medicare Modernization Act: 2007 Final Guidelines - Formularies," 2007 http://www.cms.hhs.gov/ PrescriptionDrugCovContra/Downloads/CY07FormularyGuidance.pdf (accessed 1 February 2008).
-
(2007)
Final Guidelines - Formularies
-
-
-
43
-
-
0347257056
-
Managing Psychotropic Drug Costs: Will Formularies Work?
-
H.A. Huskamp, "Managing Psychotropic Drug Costs: Will Formularies Work?" Health Affairs 22, no. 5 (2003): 84-96;
-
(2003)
Health Affairs
, vol.22
, Issue.5
, pp. 84-96
-
-
Huskamp, H.A.1
-
44
-
-
44449090753
-
-
Lieberman et al, Effectiveness of Antipsychotic Drugs; and Soumerai, Benefits and Risks of Increasing Restrictions.
-
Lieberman et al, "Effectiveness of Antipsychotic Drugs"; and Soumerai, "Benefits and Risks of Increasing Restrictions."
-
-
-
-
45
-
-
44449160653
-
-
MaineCare Advisory Committee's Prior Authorization Subcommittee Report and Recommendations on Prior Authorization for Prescription Drugs in the MaineCare and Drugs for the Elderly Programs, submitted to the Maine Department of Health and Human Services, Augusta, Maine, 19 January
-
MaineCare Advisory Committee's Prior Authorization Subcommittee Report and Recommendations on Prior Authorization for Prescription Drugs in the MaineCare and Drugs for the Elderly Programs, submitted to the Maine Department of Health and Human Services, Augusta, Maine, 19 January 2005.
-
(2005)
-
-
-
46
-
-
34249299424
-
Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First Four Months of the Medicare Prescription Drug Benefit
-
J.C. West et al., "Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First Four Months of the Medicare Prescription Drug Benefit," American Journal of Psychiatry 164, no. 5 (2007): 789-796.
-
(2007)
American Journal of Psychiatry
, vol.164
, Issue.5
, pp. 789-796
-
-
West, J.C.1
-
47
-
-
35148876967
-
-
P. Neuman et al., Medicare Prescription Drug Benefit Progress Report: Findings from a 2006 National Survey of Seniors, Health Affairs 26, no. 5 (2007): w630-w643 (published online 21 August 2007; 10.1377/hlthaff.26.5.w630).
-
P. Neuman et al., "Medicare Prescription Drug Benefit Progress Report: Findings from a 2006 National Survey of Seniors," Health Affairs 26, no. 5 (2007): w630-w643 (published online 21 August 2007; 10.1377/hlthaff.26.5.w630).
-
-
-
-
48
-
-
0029075682
-
Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Anti-Inflammatory Drugs by Medicaid Patients
-
W.E. Smalley et al., "Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Anti-Inflammatory Drugs by Medicaid Patients," New England Journal of Medicine 332, no. 24 (1995): 1612-1617;
-
(1995)
New England Journal of Medicine
, vol.332
, Issue.24
, pp. 1612-1617
-
-
Smalley, W.E.1
-
49
-
-
0037076037
-
Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors
-
and S. Schneeweiss et al., "Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors," New England Journal of Medicine 346, no. 11 (2002): 822-829.
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.11
, pp. 822-829
-
-
Schneeweiss, S.1
-
53
-
-
44449123347
-
-
CMS, Center for Medicaid and State Operations, Guidance for States on Preferred Drug Lists (PDLs) and Prior Authorization, State Medicaid Director Letter, 9 September 2004, SMDL no. 04-006, http://www.cms.hhs.gov/smdl/ downloads/smd090904.pdf (accessed 1 February 2008).
-
CMS, Center for Medicaid and State Operations, "Guidance for States on Preferred Drug Lists (PDLs) and Prior Authorization," State Medicaid Director Letter, 9 September 2004, SMDL no. 04-006, http://www.cms.hhs.gov/smdl/ downloads/smd090904.pdf (accessed 1 February 2008).
-
-
-
|